About Affymetrix

Stock Quote

AFFX (Common Stock)
Current Day's High
Current Day's Low
Current Day's Volume
Last Trade
Mar 31 16 4:00 p.m. ET

The stock price performance shown on the quote above is not necessarily indicative of future price performance

Bookmark and Share

Press Releases

Keyword Search
All Releases |2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
Thermo Fisher Scientific Announces Commercial Availability of Next-Generation Axiom Precision Medicine Research Array for Global Research Screening Initiatives
SANTA CLARA, Calif. – (July 7, 2016) – Epidemiologists and genomics researchers who want to gain a deeper understanding of human genetic variation in translational research now have access to Thermo Fisher Scientific's Axiom Precision Medicine Research Array, a powerful genotyping solution with more than 900,000 markers of biological significance for clinical research studies. The new array is available for immediate delivery for $29 per sample, with no minimum sample commitment. ... 
Thermo Fisher Scientific Completes Acquisition of Affymetrix Following Approval of Transaction by Affymetrix Stockholders
WALTHAM, Mass. & SANTA CLARA, Calif.--(BUSINESS WIRE)--Mar. 31, 2016-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Affymetrix, Inc. (NASDAQ: AFFX), a leading provider of cellular and genetic analysis products, today announced that Thermo Fisher has completed its previously announced acquisition of Affymetrix for $14.00 per share in cash, for a total purchase price of approximately $1.3 billion. Completion of th... 
Affymetrix Receives Grant for Non-Invasive Genomic Profiling of Bladder Cancer
SANTA CLARA, Calif.--(BUSINESS WIRE)--Mar. 8, 2016-- Affymetrix Inc. (NASDAQ:AFFX) today announced that it has received a grant from Innovate UK (IUK) to demonstrate the health and economic value of utilizing the company’s OncoScan® FFPE Assay Kit for non-invasive genomic profiling of bladder cancer from urine samples. Bladder cancer is the seventh most common cancer in the western world, with over 10,000 new cases diagnosed in the UK each year. P... 
Groupe Grimaud Chooses Affymetrix Genotyping Arrays for Poultry Breeding Business
SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb. 24, 2016-- Affymetrix, Inc. (NASDAQ:AFFX) announced today that one of the world’s largest producers of breeding chickens – Roussay, France-based Groupe Grimaud – will use the Axiom® genotyping platform from Affymetrix in its genomic selection and poultry breeding program. The Grimaud Novogen and Hubbard divisions will be incorporating the Affymetrix technology, and the company is already using a rabbit ge... 
Bio-Genesys and Affymetrix Partner to Offer Animal Genomic Testing Services to Professional Farming Operations
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 12, 2016-- Affymetrix, Inc. (NASDAQ:AFFX) and United Kingdom-based Bio-Genesys Diagnostics announced today that they have entered a partnership to offer commercial genotyping services. Under the terms of the agreement, the genetic testing services offered by Bio-Genesys Diagnostics for cattle, pigs, goats, sheep, and camelids will be run exclusively on Affymetrix’s technology. The partnership leverages th... 
Affymetrix Expands Agrigenomics Genotyping Portfolio with New Targeted Sequencing Solution and Array Formats
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 7, 2016-- Affymetrix, Inc. (NASDAQ:AFFX) is introducing several new agrigenomic genotyping solutions this week at the annual Plant and Animal Genome Conference (PAG XXIV). Following the company’s acquisition of Eureka Genomics in mid-2015, Affymetrix is introducing Eureka™ Genotyping Solution for low-cost, low-plex genotyping by sequencing (GBS). The company is also introducing two new array configuration... 

Back to Top >